Karachi: Liven Pharma Limited has disclosed a series of transactions involving the sale of shares by its Executive Director, Kaashif Hussain Siddique. The transactions were carried out on January 5, 2026, as per the company’s announcement under the Pakistan Stock Exchange (PSX) Regulation 5.6.4. This regulation mandates the disclosure of interests by relevant persons holding shares in the company.

According to the detailed disclosure, Siddique executed multiple sell orders on the same day, cumulatively impacting his shareholding in the company. The transactions involved the sale of 18,200 shares at varying rates ranging from 52.60 to 53.00 per share. The cumulative number of shares held by Siddique after these transactions stands at 40.41 million, representing a cumulative percentage of 43.43% of the company’s shares.

According to information available from the Pakistan Stock Exchange (PSX), the series of sales executed by Siddique is part of a regular disclosure requirement and reflects changes in the executive’s holdings. The disclosed transactions involved multiple sell orders, including a notable sale of 10,000 shares at a rate of 53.00 per share, reflecting the most significant single transaction in terms of volume.

Liven Pharma Limited falls under the designated market category of pharmaceutical companies. The disclosed transactions by Siddique are in compliance with regulatory requirements, ensuring transparency in the trading activities of executives and substantial shareholders. The transactions highlight the ongoing changes in shareholding patterns within the company, which remains a significant player in the pharmaceutical sector.